Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rovadicitinib in Hemophagocytic Lymphohistiocytosis
NCT04326348Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rovadicitinib in hemophagocytic lymphohistiocytosis (HLH), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity and Maximal tolerance dose. Status: unknown.
02
Drugs
rovadicitinib
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT04326348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326348.